Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CHOP-R + yttrium-90-ibritumomab tiuxetan + rituximab
- Development stage
- Phase 2
- Lead developer
- UPMC Hillman Cancer Center
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination regimen is a sequential chemoimmunotherapy and radioimmunotherapy protocol developed by the University of Pittsburgh for the treatment of previously untreated follicular lymphoma. The regimen consists of an induction phase with three cycles of CHOP-R (cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab), followed by consolidation with the radiopharmaceutical yttrium-90-ibritumomab tiuxetan (Zevalin), and a maintenance phase of extended rituximab therapy. The strategy aims to maximize complete response rates by combining the systemic cytotoxic effects of chemotherapy with the targeted antibody-mediated depletion and localized beta-radiation delivery of radioimmunotherapy, while minimizing long-term toxicity by limiting the number of chemotherapy cycles. The primary biological target is the CD20 antigen expressed on the surface of B-lymphocytes.
- Other names
- CHOP-R followed by Zevalin and RituxanCHOP-R + Zevalin + RituximabCHOP-R + Y90-Ibritumomab Tiuxetan + Rituximab
02
Targets
CD20 (B-lymphocyte antigen CD20)DNAGR (Glucocorticoid receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on CHOP-R + yttrium-90-ibritumomab tiuxetan + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CHOP-R + yttrium-90-ibritumomab tiuxetan + rituximab.